Kermode Biotechnologies develops vaccines targeting the African Swine Fever Virus (ASFV) by utilizing computational methods to identify vulnerable viral structures and employing protein antigen subunits to stimulate robust immune responses in swine. This approach addresses the critical threat of ASFV, which has a 100% mortality rate in infected animals, thereby protecting livestock and enhancing food security for farmers globally.
Funding
$1.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
African Swine Fever Virus (ASFV) poses a significant threat to the global swine industry due to its 100% mortality rate in infected animals. The rapid spread of ASFV can devastate commercial swine industries, leading to substantial economic losses and impacting food security. Currently, there is a lack of effective vaccines or treatments to combat ASFV outbreaks.
Solution
Kermode Biotechnologies is developing novel vaccines and antibody therapeutics to combat the African Swine Fever Virus (ASFV). The company utilizes computational methods to identify vulnerable targets in the virus's structure, genetic composition, and replication cycle. By focusing on these weak points, Kermode Biotechnologies aims to develop targeted interventions that can effectively prevent and treat ASFV infections in swine. Their approach involves deploying state-of-the-art antibody discovery platforms to isolate therapeutic candidates with the highest potential to protect livestock. The company's goal is to provide swine with long-lasting in vivo responses, ultimately safeguarding global swine populations and enhancing food security.
Target Audience
The primary target audience includes swine farmers, commercial swine industries, and animal health organizations seeking to protect swine populations from ASFV.
Features
- Computational identification of vulnerable targets in ASFV's structure and replication cycle
- Antibody discovery platforms for isolating therapeutic candidates
- Development of protein antigen subunit vaccines to stimulate robust immune responses
- Focus on achieving long-lasting in vivo protection against ASFV
- Therapeutic pipeline for antibody and anti-viral protein development
- Swine studies to evaluate vaccine and therapeutic efficacy